companiesCompany

TransThera Sciences

Chinese biotech running the first phase 3 of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs.

Tinengotinib (TT-00420) is a multi-kinase inhibitor potent against FGFR2 kinase-domain resistance mutations; FIRST-308 (phase 3 vs physician's choice chemotherapy in FGFR-altered, FGFRi-refractory cholangiocarcinoma) dosed its first US patient in 2025.

Headquarters

Nanjing, CN

Type

biotech

Website

www.transtherabio.com

Products

Phase 3Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)

A next-generation FGFR inhibitor designed to work after pemigatinib or futibatinib stop working, now in a global phase 3.

Connected

Pages like this

not linked directly; found by shared links

Trial
FIRST-308
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
Term
FGFR2 fusions and rearrangements
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
Idea
ctDNA-guided switching among FGFR inhibitors
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
Target
FGFR2
Shares Tinengotinib, Biliary tract cancer (cholangiocarcinoma).

cancers

1

Biliary tract cancer (cholangiocarcinoma)

fronts

1

Targeted Therapy

drugs

1

Phase 3Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)